Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Oncternal Therapeutics ( (ONCT) ) has shared an announcement.
Oncternal Therapeutics, Inc. is reducing its workforce by 37%, approximately 10 employees, to slash operating expenses and focus on strategic business development for its clinical programs. This cut, including the departure of Chief Medical Officer Dr. Salim Yazji, is part of cost-saving measures as Oncternal halts clinical trials for two cancer treatments, ONCT-534 and ONCT-808, due to insufficient clinical benefits and high development costs. Oncternal is now pursuing strategic alternatives, such as asset sales or mergers, to maximize shareholder value while pausing product development activities.
For a thorough assessment of ONCT stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue